SCRS Resource Guide Network

Sites, Sponsors, CROs: Discover the solutions your clinical research teams need with SCRS.

Endo Pharmaceuticals Inc.

Helping everyone we serve live their best life.

Endo Pharmaceuticals Inc.

At Endo, our far-reaching vision is simple: to help everyone we serve live their best life. As a specialty pharmaceutical company, we’re motivated by a strong sense of purpose to find better ways to meet unique medical needs.

Our global team of passionate employees understands the importance of their work. We’re dedicated to supporting one another as we connect with communities and foster partnerships that elevate quality-of-life and bring the best treatments forward.

Our uncompromising commitment results in the delivery of life-enhancing therapies. From intelligent product selection to commercialization, we strive to make a meaningful, tangible impact to help everyone live their best life.

Endo has global headquarters in Dublin, Ireland and its U.S. corporate office in Malvern, Pennsylvania.


Endo International plc News ReleasesEndo International plc News Releases 
  • Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting September 21, 2023 7:45am

    DUBLIN , Sept. 21, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Orthopaedic Foot & Ankle Society's (AOFAS) annual
    View this post

  • Paladin Labs Announced Favourable CADTH Recommendation for XCOPRI™ (cenobamate tablets) Français September 12, 2023 7:30am

    MONTREAL, Sept. 12, 2023 /CNW/ -- Paladin Labs Inc. announced today that the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended that XCOPRI ™  (cenobamate tablets) be publicly reimbursed as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy
    View this post


    DUBLIN , Aug. 8, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023 .     SECOND-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended June 30 , Six Months Ended June 30 , 2023 2022
    View this post

  • Endo Announces First Patient Enrolled in Registry of Peyronie's Disease July 20, 2023 7:30am

    DUBLIN , July 20, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie's disease), a non-interventional registry of up to
    View this post

  • Endo Launches Bivalirudin Injection in Ready-to-Use Vials July 18, 2023 4:30pm

    Only ready-to-use liquid format of bivalirudin on the market Does not require reconstitution, dilution or mixing, which helps increase efficiency for hospitals and healthcare providers DUBLIN , July 18, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile
    View this post

  • Endo and Premier, Inc. Collaborate to Address Pitocin® (oxytocin injection, USP) Shortage July 17, 2023 4:30pm

    Strategic effort aims to bring stable, quality supply to providers and enhanced pricing predictability for critical labor and delivery drug CHARLOTTE, N.C. and DUBLIN , July 17, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) and Premier, Inc.
    View this post

Web Site: endo.com